Systemic Infusion of Expanded CD133⁺ Cells and Expanded CD133⁺ Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI

Table 1

Echocardiographic parameters of the left ventricle pre- and posttreatment.

Group	LVEF (%); Pretreatment	LVEF (%); Posttreatment	EDV (mL); Pretreatment	EDV (mL); Posttreatment	ESV (mL); Pretreatment	ESV (mL); Posttreatment
EVs	29.7; (19.9/42)	33.8; (24.3/56.7)	0.60; (0.45/0.76)	1.02; (0.71/1.35)	0.41; (0.27/0.60)	0.72; (0.31/1.02)
CD133+	32.3 (20.2/38.6)	34.7; (14.8/54.8)	0.62; (0.44/0.75)	0.88; (0.54/1.32)	0.45; (0.27/0.56)	0.59; (0.25/1.12)
Vehicle	29.3; (26.5/42.4)	33.5; (23.1/44.5)	0.67; (0.44/0.84)	1.12; (0.67/1.36)	0.46; (0.31/0.60)	0.68; (0.44/0.98)
Control	60.4; (58.3/64.7)	65.3; (61.4/70.8)	0.49; (0.42/0.60)	0.57; (0.52/0.61)	0.19; (0.16/0.24)	0.18; (0.17/0.23)

LVEF: left ventricular ejection fraction; EDV: end-diastolic volume; ESV: end-systolic volume; EVs: transplanted with expanded CD133⁺ cell-derived EVs; CD133⁺: transplanted with expanded CD133⁺ cells; vehicle: treated with PBS; control: healthy animals ( to 8 per group). Data are presented as median (minimum/maximum). Significant difference between pre- and posttreatment moments of each group ().